Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Robert H. Collins(Texas Oncology), John Nemunaitis(Gradalis (United States)), Stacey Goodman(Texas Oncology), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Joseph H. Antin(Dana-Farber Cancer Institute), William S. Dalton(Texas Oncology), Ofer Shpilberg(Texas Oncology), Alan F. List(TE Laboratories (Ireland)), Sergio Giralt(Memorial Sloan Kettering Cancer Center), William R. Drobyski(Medical College of Wisconsin), David Porter(University of Pennsylvania), Angela Chetrit(Texas Oncology), S N Wolff(Texas Oncology), Nadine Ognoskie(Texas Oncology), Hu Wh(Texas Oncology), Catherine M. Verfaillie(KU Leuven)
Cited by 1,258
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k